Parametric Portfolio Associates LLC boosted its stake in Entellus Medical, Inc. (NASDAQ:ENTL) by 5.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,888 shares of the medical technology company’s stock after buying an additional 573 shares during the period. Parametric Portfolio Associates LLC’s holdings in Entellus Medical were worth $150,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Swiss National Bank boosted its position in shares of Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after buying an additional 8,800 shares during the period. TD Asset Management Inc. purchased a new position in shares of Entellus Medical during the first quarter valued at about $279,000. Eqis Capital Management Inc. boosted its position in shares of Entellus Medical by 22.8% in the first quarter. Eqis Capital Management Inc. now owns 33,475 shares of the medical technology company’s stock valued at $462,000 after buying an additional 6,223 shares during the period. Perkins Capital Management Inc. boosted its position in shares of Entellus Medical by 6.5% in the first quarter. Perkins Capital Management Inc. now owns 60,017 shares of the medical technology company’s stock valued at $828,000 after buying an additional 3,667 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Entellus Medical by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 78,800 shares of the medical technology company’s stock valued at $1,495,000 after buying an additional 14,800 shares during the period. 76.84% of the stock is owned by institutional investors and hedge funds.
Shares of Entellus Medical, Inc. (NASDAQ:ENTL) opened at 17.18 on Wednesday. Entellus Medical, Inc. has a 52 week low of $11.47 and a 52 week high of $22.63. The stock has a 50 day moving average of $16.58 and a 200-day moving average of $15.07. The company’s market capitalization is $376.52 million.
Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. The company had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.27) earnings per share. On average, analysts anticipate that Entellus Medical, Inc. will post ($1.62) EPS for the current year.
Several brokerages have issued reports on ENTL. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub cut shares of Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Canaccord Genuity set a $18.00 target price on shares of Entellus Medical and gave the stock a “hold” rating in a report on Monday, May 22nd. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Entellus Medical in a report on Wednesday, July 12th. Finally, William Blair reaffirmed an “outperform” rating on shares of Entellus Medical in a report on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $21.83.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical, Inc. (NASDAQ:ENTL).
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
